These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 26275801)

  • 1. Immune-modulators to combat hepatitis B virus infection: From IFN-α to novel investigational immunotherapeutic strategies.
    Isorce N; Lucifora J; Zoulim F; Durantel D
    Antiviral Res; 2015 Oct; 122():69-81. PubMed ID: 26275801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status of immunomodulatory therapy in chronic hepatitis B, fifty years after discovery of the virus: Search for the "magic bullet" to kill cccDNA.
    Zhang E; Kosinska A; Lu M; Yan H; Roggendorf M
    Antiviral Res; 2015 Nov; 123():193-203. PubMed ID: 26476376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapeutic interventions in chronic hepatitis B virus infection: a review.
    Wang L; Zou ZQ; Liu CX; Liu XZ
    J Immunol Methods; 2014 May; 407():1-8. PubMed ID: 24747918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in therapeutics for chronic hepatitis B.
    Yang N; Bertoletti A
    Hepatol Int; 2016 Mar; 10(2):277-85. PubMed ID: 26363922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha.
    Rico MA; Quiroga JA; Subirá D; Castañón S; Esteban JM; Pardo M; Carreño V
    Hepatology; 2001 Jan; 33(1):295-300. PubMed ID: 11124848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon and Hepatitis B: Current and Future Perspectives.
    Ye J; Chen J
    Front Immunol; 2021; 12():733364. PubMed ID: 34557195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B virus-specific T-cell responses during IFN administration in a small cohort of chronic hepatitis B patients under nucleos(t)ide analogue treatment.
    Sprinzl MF; Russo C; Kittner J; Allgayer S; Grambihler A; Bartsch B; Weinmann A; Galle PR; Schuchmann M; Protzer U; Bauer T
    J Viral Hepat; 2014; 21(9):633-41. PubMed ID: 24251783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic hepatitis B: A wave of new therapies on the horizon.
    Block TM; Rawat S; Brosgart CL
    Antiviral Res; 2015 Sep; 121():69-81. PubMed ID: 26112647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of interferon-mediated antiviral immunity by hepatitis B virus: an overview of research progress.
    Guo P
    Scand J Immunol; 2013 Sep; 78(3):230-7. PubMed ID: 23790137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging pipeline drugs for hepatitis B infection.
    Cox N; Tillmann H
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):713-29. PubMed ID: 22195605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Comparison of Interferon-α Subtypes Reveals Potent Hepatitis B Virus Suppression by a Concerted Action of Interferon-α and Interferon-γ Signaling.
    Chen J; Li Y; Lai F; Wang Y; Sutter K; Dittmer U; Ye J; Zai W; Liu M; Shen F; Wu M; Hu K; Li B; Lu M; Zhang X; Zhang J; Li J; Chen Q; Yuan Z
    Hepatology; 2021 Feb; 73(2):486-502. PubMed ID: 32333814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues.
    Dusheiko G
    Liver Int; 2013 Feb; 33 Suppl 1():137-50. PubMed ID: 23286858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune balance in Hepatitis B Infection: Present and Future Therapies.
    Vyas AK; Jindal A; Hissar S; Ramakrishna G; Trehanpati N
    Scand J Immunol; 2017 Jul; 86(1):4-14. PubMed ID: 28387980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The E genotype of hepatitis B: clinical and virological characteristics, and response to interferon.
    Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
    J Infect; 2014 Jul; 69(1):81-7. PubMed ID: 24631900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for Chronic Hepatitis B Virus Infection.
    Bertoletti A; Le Bert N
    Gut Liver; 2018 Sep; 12(5):497-507. PubMed ID: 29316747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural history and prognosis of hepatitis B.
    Fattovich G
    Semin Liver Dis; 2003 Feb; 23(1):47-58. PubMed ID: 12616450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus.
    Wang FS; Zhang Z
    Expert Rev Gastroenterol Hepatol; 2009 Oct; 3(5):499-512. PubMed ID: 19817672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of chronic hepatitis B: Evolution over two decades.
    Yuen MF; Lai CL
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Host factor-targeted hepatitis B virus therapies.
    Gehring A; Bertoletti A; Tavis JE
    Intervirology; 2014; 57(3-4):158-62. PubMed ID: 25034483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-antigen-specific and antigen-specific immune therapies for chronic hepatitis B: evidences from laboratory benches and patient's bedsides.
    Akbar SM; Al-Mahtab M; Khan MS
    Expert Opin Biol Ther; 2013 Jul; 13(7):1063-74. PubMed ID: 23581572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.